43.00
-0.60 (-1.38%)
| Previous Close | 43.60 |
| Open | 43.58 |
| Volume | 313,999 |
| Avg. Volume (3M) | 567,992 |
| Market Cap | 1,955,593,088 |
| Price / Earnings (TTM) | 97.73 |
| Price / Sales | 1.62 |
| Price / Book | 1.56 |
| 52 Weeks Range |
| Profit Margin | 1.87% |
| Operating Margin (TTM) | -4.31% |
| Diluted EPS (TTM) | 0.460 |
| Quarterly Revenue Growth (YOY) | 9.60% |
| Quarterly Earnings Growth (YOY) | 55.40% |
| Total Debt/Equity (MRQ) | 30.69% |
| Current Ratio (MRQ) | 1.38 |
| Operating Cash Flow (TTM) | 163.69 M |
| Levered Free Cash Flow (TTM) | 122.12 M |
| Return on Assets (TTM) | 0.35% |
| Return on Equity (TTM) | 1.73% |
Market Trend
| Short Term | Medium Term | ||
| Industry | Health Information Services (US) | Bearish | Mixed |
| Health Information Services (Global) | Bearish | Mixed | |
| Stock | Omnicell, Inc. | Bullish | Bullish |
AIStockmoo Score
| Analyst Consensus | 2.0 |
| Insider Activity | 3.0 |
| Price Volatility | -2.0 |
| Technical Moving Averages | 0.0 |
| Technical Oscillators | 0.5 |
| Average | 0.70 |
|
Omnicell Inc provides automation and business analytics software for healthcare providers. The company is engaged in transforming the pharmacy and nursing care delivery model. The company helps its customers define and deliver cost-effective medication management designed to equip and empower pharmacists and nurses to focus on patient care rather than administrative tasks and drive improved clinical, operational, and financial outcomes across all care settings. The company derives the majority of its revenue from the United States. |
|
| Sector | Healthcare |
| Industry | Health Information Services |
| Investment Style | Small Core |
| % Held by Insiders | 1.78% |
| % Held by Institutions | 104.60% |
No data within this time range.
| Name | Avg. Buy ($) | Avg. Sell ($) | Net Quantity | Net Value ($) |
|---|---|---|---|---|
| BAUER JOANNE B | 43.16 | - | 5,027 | 216,965 |
| BOUSA EDWARD PETER | 43.16 | - | 4,603 | 198,665 |
| GARRETT MARY | 43.16 | - | 5,027 | 216,965 |
| GHOSHAL KAUSHIK | 43.16 | - | 4,603 | 198,665 |
| PARRISH MARK W | 43.16 | - | 4,845 | 209,110 |
| SCOTT BRUCE E | 43.16 | - | 4,627 | 199,701 |
| SEIM ROBIN GENE | 43.16 | - | 4,845 | 209,110 |
| VOYNICK EILEEN J. | 43.16 | - | 4,785 | 206,521 |
| Aggregate Net Quantity | 38,362 | |||
| Aggregate Net Value ($) | 1,655,704 | |||
| Aggregate Avg. Buy ($) | 43.16 | |||
| Aggregate Avg. Sell ($) | - | |||
| Name | Holder | Date | Type | Quantity | Price | Value ($) |
|---|---|---|---|---|---|---|
| GARRETT MARY | Director | 01 Jun 2026 | Acquired (+) | 5,027 | 43.16 | 216,965 |
| GHOSHAL KAUSHIK | Director | 01 Jun 2026 | Acquired (+) | 4,603 | 43.16 | 198,665 |
| BAUER JOANNE B | Director | 01 Jun 2026 | Acquired (+) | 5,027 | 43.16 | 216,965 |
| PARRISH MARK W | Director | 01 Jun 2026 | Acquired (+) | 4,845 | 43.16 | 209,110 |
| SEIM ROBIN GENE | Director | 01 Jun 2026 | Acquired (+) | 4,845 | 43.16 | 209,110 |
| BOUSA EDWARD PETER | Director | 01 Jun 2026 | Acquired (+) | 4,603 | 43.16 | 198,665 |
| VOYNICK EILEEN J. | Director | 01 Jun 2026 | Acquired (+) | 4,785 | 43.16 | 206,521 |
| SCOTT BRUCE E | Director | 01 Jun 2026 | Acquired (+) | 4,627 | 43.16 | 199,701 |
The support, resistance and trendline levels presented has been generated by an artificial intelligence (AI) model and should be interpreted with caution.
Portfolio
| Realized Profit | - |
| Unrealized Profit | - |
| Dividend Received 2026 | - |
| Total Profit | - |
| Avg. Return | - |
| Quantity (Buy) | - |
| Avg. Price (Buy) | - |
| Quantity (Sold) | - |
| Avg. Price (Sold) | - |